Xolair (ZO-lair), the first biologic therapy for moderate to severe persistent asthma

July 2003

Genentech is now marketing Xolair (ZO-lair), the first biologic therapy for moderate to severe persistent asthma.

Xolair (omalizumab) is an important new option...but only for a select group of patients.

It's only for allergic asthma in patients age 12 and up... when inhaled steroids aren't enough.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote